{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Skin+Melanoma&page=6", "query": { "condition": "Stage IV Skin Melanoma", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 654, "total_pages": 66, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Skin+Melanoma&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Skin+Melanoma&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T23:42:55.508Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02094872", "title": "Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IIIA Melanoma", "Stage IIIB Melanoma", "Stage IIIC Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "cytology specimen collection procedure", "type": "OTHER" }, { "name": "MEK 162 therapy or molecularly targeted therapy", "type": "DRUG" }, { "name": "therapeutic procedure", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "quality-of-life assessment", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG", "PROCEDURE" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2014-05", "completion_date": "2018-12", "has_results": true, "last_update_posted_date": "2020-01-02", "last_synced_at": "2026-10-13T23:42:55.508Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Jacksonville, Florida + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02094872" }, { "nct_id": "NCT02200562", "title": "Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stage III or IV Melanoma" ], "interventions": [ { "name": "ipilimumab and dabrafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2014-12", "completion_date": "2017-01-20", "has_results": false, "last_update_posted_date": "2017-03-01", "last_synced_at": "2026-10-13T23:42:55.508Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02200562" }, { "nct_id": "NCT05896839", "title": "Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8", "Metastatic Basal Cell Carcinoma", "Metastatic Carcinoma in the Skin", "Metastatic Melanoma", "Metastatic Merkel Cell Carcinoma", "Metastatic Skin Squamous Cell Carcinoma", "Unresectable Basal Cell Carcinoma", "Unresectable Melanoma", "Unresectable Merkel Cell Carcinoma", "Unresectable Skin Squamous Cell Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Kidney Biopsy", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2024-07-24", "completion_date": "2027-01-31", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-10-13T23:42:55.508Z", "location_count": 26, "location_summary": "La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 18 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05896839" }, { "nct_id": "NCT00669019", "title": "Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IIA Melanoma", "Stage IIB Melanoma", "Stage IIC Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "saracatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2006-07", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2014-05-21", "last_synced_at": "2026-10-13T23:42:55.508Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00669019" }, { "nct_id": "NCT00668512", "title": "Intratumoral Injection Of Alpha-Gal Glycosphingolipids", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Antimelanoma injection of GSL alpha-Gal", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Massachusetts, Worcester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 12, "start_date": "2007-03", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2015-03-19", "last_synced_at": "2026-10-13T23:42:55.508Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00668512" }, { "nct_id": "NCT03025256", "title": "Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acral Lentiginous Melanoma", "Central Nervous System Melanoma", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Leptomeningeal Neoplasm", "Melanocytoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Melanoma", "Metastatic Mucosal Melanoma", "Metastatic Uveal Melanoma", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2018-05-02", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-13T23:42:55.508Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03025256" }, { "nct_id": "NCT00033956", "title": "Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "IL-2 Induced Hypotension" ], "interventions": [ { "name": "M40403", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MetaPhore Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2001-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-13T23:42:55.508Z", "location_count": 3, "location_summary": "Chicago, Illinois • Portland, Oregon • Salt Lake City, Utah", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Portland", "state": "Oregon" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00033956" }, { "nct_id": "NCT00453050", "title": "Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma (Skin)", "Metastatic Cancer" ], "interventions": [ { "name": "imiquimod", "type": "DRUG" }, { "name": "indocyanine green solution", "type": "DRUG" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2006-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-05-06", "last_synced_at": "2026-10-13T23:42:55.508Z", "location_count": 1, "location_summary": "Tulsa, Oklahoma", "locations": [ { "city": "Tulsa", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT00453050" }, { "nct_id": "NCT00020540", "title": "Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Kidney Cancer", "Melanoma (Skin)" ], "interventions": [ { "name": "recombinant CD40-ligand", "type": "BIOLOGICAL" }, { "name": "recombinant flt3 ligand", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": null, "start_date": "2001-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-30", "last_synced_at": "2026-10-13T23:42:55.508Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020540" }, { "nct_id": "NCT00005617", "title": "Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "dendritic cell-MART-1 peptide vaccine", "type": "BIOLOGICAL" }, { "name": "leukapheresis", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1997-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-08-03", "last_synced_at": "2026-10-13T23:42:55.508Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005617" } ] }